Drugs / recombinant fowlpox-TRICOM vaccine
recombinant fowlpox-TRICOM vaccine
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00072137 | Oct 2003 → Dec 2009 | bladder adenocarcinoma, bladder squamous cell carcinoma, urothelial carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00030693 | Dec 2001 → Apr 2010 | cancer of unknown primary site | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00021424 | Jun 2001 → ? | head and neck cancer, metastatic malignant neoplasm | National Institute on Deafness and Other Communication Disorders (NIDCD) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00087373 | Jun 2004 → Feb 2006 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox-TRICOM vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00030693 ↗ |
| Known as | rF-TRI | “Patients receive recombinant fowlpox-TRICOM vaccine (rF-TRI) intralesionally once on weeks 0, 3, and 8.” NCT00021424 ↗ |
| Known as | rF-TRICOM (B7.1.iCAM1-LFA3-Fowlpox) | “rF-TRICOM (B7.1.iCAM1-LFA3-Fowlpox)” NCT00030693 ↗ |
| Modality | Vaccine | “fowlpox-TRICOM vaccine” NCT00030693 ↗ |
| Route | Other | “Patients receive recombinant fowlpox-TRICOM vaccine (rF-TRI) intralesionally once on weeks 0, 3, and 8.” NCT00021424 ↗ |